How to Choose the Right Preferred Term (PT) in MedDRA Coding

Why Preferred Term Selection Matters

The Preferred Term (PT) is the cornerstone of MedDRA coding in clinical trials and pharmacovigilance. Each PT represents a unique medical concept that enables harmonized reporting of adverse events across studies and regions. The correct choice of PT ensures regulatory compliance, supports accurate signal detection, and allows for meaningful safety analysis. Conversely, misclassification at the PT level can lead to erroneous safety conclusions, missed signals, or regulatory findings during inspections.

For example, if an investigator records “fits,” coders must map this to the PT “Convulsion.” Selecting “Epilepsy” instead would be inappropriate because epilepsy implies a chronic condition, not an acute event. Regulators such as the FDA, EMA, and CDSCO expect sponsors to have robust processes and SOPs to ensure accuracy in PT selection.

Since PTs are used in aggregate safety reports such as DSURs, PSURs, and IND safety reports, the reliability of these submissions depends on consistent and accurate PT coding. Training coders and establishing coding conventions are therefore essential.

Process of Selecting a Preferred Term

Coders usually begin with the investigator-reported term, which is mapped to the Lowest Level Term (LLT). From there, MedDRA automatically links the LLT to a PT. The coder’s role is to ensure that the chosen PT truly reflects the intended meaning of the original investigator term.

The selection process typically involves:

1. Reviewing the verbatim term: Understand context and clinical meaning.
2. Identifying LLT matches: Search MedDRA for possible LLTs that fit.
3. Evaluating PT linkage: Ensure the LLT maps to the most accurate PT.
4. Applying coding conventions: Follow sponsor or CRO guidelines for standardization.
5. Quality check: Verify accuracy through peer review or safety database controls.

For example, the investigator term “stomach upset” could map to LLTs such as “Abdominal discomfort” or “Dyspepsia.” The coder must select the PT that best reflects the clinical description, likely “Dyspepsia.”

Examples of Correct PT Selection

Below is a table illustrating how PTs should be chosen for different investigator terms:

These examples show that careful PT selection maintains the clinical intent of the original term while ensuring regulatory-standard consistency.

Challenges in Choosing the Right PT

Despite clear rules, coders often face challenges in selecting PTs:

• Ambiguity: Investigator terms may be vague, such as “feeling unwell,” which lacks clinical specificity.
• Multiple options: Several LLTs may map to different PTs, requiring coder judgment.
• Updates in MedDRA: New PTs are introduced in biannual updates, requiring re-coding or reconciliation.
• Inter-coder variability: Different coders may select different PTs for the same verbatim term.
• System errors: Automated coding tools may misclassify terms without proper review.

For example, “fainting” could map to PTs such as “Syncope” or “Loss of consciousness.” Choosing the right PT depends on clinical context. Without clear conventions, inconsistencies may arise across studies.

Regulatory Expectations and Inspection Findings

Regulators expect traceability and consistency in PT selection. Common inspection findings include:

• Incorrect mapping of investigator terms to PTs.
• Lack of documentation for coding decisions.
• Failure to update PT assignments after MedDRA version upgrades.
• Inconsistent PT use across trials, leading to skewed safety analyses.

For example, an inspection may reveal that the same investigator term “blood clot” was coded as “Thrombosis” in one study and “Embolism” in another. Regulators view this as a major compliance gap. Sponsors are expected to have coding conventions and regular audits to prevent such inconsistencies.

Best Practices for PT Selection

To ensure accuracy in MedDRA coding, clinical teams should adopt these best practices:

• Develop detailed coding conventions with examples for common terms.
• Train coders and CRAs regularly on MedDRA updates and PT selection principles.
• Use hybrid auto/manual coding to balance efficiency with accuracy.
• Perform peer reviews and audits of coded terms to identify errors.
• Reconcile coding across studies to maintain consistency in aggregate reporting.

External resources such as the ClinicalTrials.gov database provide examples of standardized safety reporting, reinforcing the importance of accurate coding practices.

Key Takeaways

Choosing the right PT in MedDRA coding is critical for regulatory compliance, safety analysis, and inspection readiness. Clinical teams must:

• Understand the MedDRA hierarchy and its linkages from LLT to PT.
• Apply clear conventions to reduce ambiguity in coding.
• Ensure PT selection reflects the true clinical meaning of investigator terms.
• Document and audit coding decisions for consistency across trials.
• Stay updated with MedDRA version changes and retrain staff accordingly.

By applying these principles, sponsors and CROs can ensure that safety data is accurate, consistent, and aligned with global regulatory expectations.

Understanding MedDRA and Its Importance in Clinical Trials

Introduction to MedDRA

The Medical Dictionary for Regulatory Activities (MedDRA) is an internationally standardized medical terminology developed under the auspices of the International Council for Harmonisation (ICH). It is the global standard for coding adverse events, medical histories, indications, and procedures across clinical trials and post-marketing surveillance. Regulators such as the FDA, EMA, MHRA, PMDA, and CDSCO require the use of MedDRA for consistent reporting of adverse events.

MedDRA provides a common language that allows harmonized reporting of clinical and safety data across companies, regions, and regulatory submissions. This prevents misinterpretations that could arise if sponsors used different medical terminologies. For example, one sponsor might describe an event as “heart attack,” while another uses “myocardial infarction.” MedDRA coding ensures both are standardized under the same Preferred Term (PT) for regulatory analysis.

The dictionary is used throughout the product lifecycle: from early phase clinical trials to post-marketing pharmacovigilance. In safety reporting databases such as the FDA FAERS and the EMA EudraVigilance, MedDRA ensures that safety signals are consistently captured and analyzed across millions of case reports.

Why MedDRA Is Used in Clinical Trials

MedDRA is not just a vocabulary; it is a regulatory requirement and an analytical tool. Its use offers several key benefits:

• Regulatory compliance: All IND, NDA, BLA, and CTA submissions must use MedDRA coding for adverse events.
• Consistency: Ensures uniform representation of medical concepts across trials, preventing duplication or misclassification.
• Signal detection: Facilitates statistical analyses to identify potential safety issues across large datasets.
• Global harmonization: Enables cross-regional reporting under FDA, EMA, and WHO guidelines.
• Audit readiness: Provides clear documentation and coding traceability during GCP and pharmacovigilance inspections.

For example, in oncology trials, adverse events such as “low white blood cell count” are coded under the MedDRA PT “Neutropenia.” This standardization enables consistent analysis of hematological toxicity across multiple compounds and studies.

Structure of MedDRA and Its Application

MedDRA is hierarchical, consisting of five levels:

1. Lowest Level Terms (LLTs): Lay or specific terms entered by investigators (e.g., “heart attack”).
2. Preferred Terms (PTs): Standardized terms for analysis (e.g., “Myocardial infarction”).
3. High Level Terms (HLTs): Group of related PTs (e.g., “Ischemic coronary artery disorders”).
4. High Level Group Terms (HLGTs): Broader groupings (e.g., “Coronary artery disorders”).
5. System Organ Class (SOC): Highest level, grouping by organ system (e.g., “Cardiac disorders”).

By applying this structure, sponsors ensure that adverse events can be reviewed both in detail (PT-level) and broadly (SOC-level). Regulatory reviewers use SOC-level summaries to evaluate system-wide toxicities, while safety physicians use PT-level data for case-level assessments.

A sample MedDRA coding workflow might look like this:

This process demonstrates how MedDRA transforms site-reported terms into standardized codes for regulatory use.

Challenges and Limitations of MedDRA Use

While MedDRA brings enormous benefits, it is not without challenges:

• Ambiguous terms: Investigators may use vague language like “unwell,” which requires careful coding to avoid misclassification.
• Version updates: MedDRA is updated biannually (March and September). Sponsors must reconcile coding across versions, which can affect ongoing trials.
• Training needs: CRAs, coders, and safety teams must be trained regularly on MedDRA use and version changes.
• Auto-coding risks: Automated systems can misclassify terms if not reviewed by trained coders, especially for complex events.
• Consistency across teams: Large sponsors with multiple coding teams must maintain coding conventions to avoid discrepancies.

For example, if one coder selects the PT “Headache” for the term “Migraine” while another selects “Migraine,” analyses of central nervous system toxicity could be distorted. SOPs and coding guidelines are critical to mitigate such risks.

Regulatory Expectations and Inspections

Regulatory authorities expect sponsors to demonstrate traceability in MedDRA coding. During inspections, common findings include:

• Incorrect coding of investigator-reported terms.
• Lack of documentation explaining coding choices.
• Failure to update coding after MedDRA version upgrades.
• Inconsistent coding across related studies.

To prepare, sponsors should maintain coding conventions documents, perform regular coding reviews, and reconcile data after each MedDRA update. Training logs for CRAs and coders are often reviewed by inspectors as proof of competency.

Best Practices for MedDRA Implementation

To maximize the benefits of MedDRA and ensure regulatory compliance, clinical teams should adopt these best practices:

• Establish clear SOPs for coding workflows and version updates.
• Use hybrid coding: auto-coding for straightforward terms, manual coding for complex/ambiguous cases.
• Conduct regular coding consistency checks and audits.
• Train CRAs, coders, and pharmacovigilance staff on MedDRA fundamentals and updates.
• Reconcile coded data across studies and ensure alignment in DSURs and PSURs.

For example, a sponsor may implement quarterly coding review boards to evaluate difficult terms and ensure consistent PT selection across all trials.

External resources such as the WHO International Clinical Trials Registry provide references to safety reporting standards, reinforcing the need for harmonized MedDRA use worldwide.

Key Takeaways

MedDRA is the global standard for adverse event coding and is indispensable for regulatory compliance, data integrity, and safety signal detection. Clinical teams must:

• Understand the hierarchical structure of MedDRA (LLT → PT → HLT → HLGT → SOC).
• Apply consistent coding practices to avoid misclassification.
• Ensure timely updates with each new MedDRA version release.
• Train staff regularly to maintain competency in coding practices.
• Maintain audit-ready documentation and coding conventions.

By implementing robust MedDRA processes, sponsors and CROs ensure that safety data is reliable, regulators receive accurate submissions, and patient safety remains at the core of clinical research.